文献速递前列腺癌

基于磁共振成像的前列腺癌风险计算器及决策策略在两个欧洲大型医学中心的表现

Performance of magnetic resonance imaging-based prostate cancer risk calculators and decision strategies in two large European medical centres.
PubMed 文献 · BJU Int · 2023-09-12

回顾性纳入两个欧洲中心940例接受前列腺MRI及靶向和/或系统穿刺的男性,评估18种基于MRI的多变量风险计算器(MRI-RC)及基于MRI和PSA密度的二分决策策略。Van Leeuwen模型与RPCRC判别力最佳(AUC均为0.86),决策曲线分析临床效用最高为Van Leeuwen模型。在10%阈值下Van Leeuwen模型可避免22%穿刺、漏诊1.8%有临床意义前列腺癌(csPCa),RPCRC避免20%穿刺、漏诊2.6% csPCa。多变量MRI-RC优于仅基于MRI和PSAD的二分策略。

要点

  • Van Leeuwen模型与RPCRC的AUC均为0.86,在可全队列评估的MRI-RC中判别力最佳。
  • 10%阈值下Van Leeuwen模型避免22%穿刺、漏诊1.8% csPCa;RPCRC避免20%穿刺、漏诊2.6% csPCa。
  • 多变量MRI-RC表现优于所有仅基于MRI发现和PSAD的二分决策策略。

核心结论

  • 即使在高风险队列中,穿刺决策支持工具可避免许多前列腺穿刺,同时漏诊极少数csPCa病例。
  • Van Leeuwen模型临床效用最高,其次为RPCRC。
  • 多变量MRI-RC表现更优,应优先于仅基于MRI和PSAD的决策策略。

研究设计与样本

  • 回顾性纳入两个欧洲大型医学中心接受前列腺MRI及后续靶向和/或系统前列腺穿刺的男性。
  • 通过PubMed检索确定可用的决策支持工具。
  • 共纳入940例男性,其中507例(54%)患有csPCa。
  • 评估了18种多变量风险计算器(MRI-RC)以及基于MRI发现和PSAD阈值的二分穿刺决策策略。
  • 在5%–20%风险阈值下,通过校准、判别、决策曲线分析(DCA)以及避免穿刺数与漏诊csPCa数评估表现,包括再校准前后。

主要发现

  • 纳入男性中位(四分位距)年龄68(63–72)岁,PSA 9(7–15)ng/mL,PSAD 0.20(0.13–0.32)ng/mL²。
  • 在可全队列评估的MRI-RC中,Van Leeuwen模型和RPCRC判别力最佳,受试者工作特征曲线下面积(AUC)均为0.86。
  • DCA显示Van Leeuwen模型临床效用最高,其次为RPCRC。
  • 10%阈值下Van Leeuwen模型避免22%的穿刺、漏诊1.8%的csPCa,RPCRC避免20%的穿刺、漏诊2.6%的csPCa。
  • 多变量模型表现优于所有仅基于MRI发现和PSAD的二分决策策略。

临床怎么用

  • 作者结论认为多变量MRI-RC表现更优,应优先于仅基于MRI和PSAD的决策策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the performance of currently available biopsy decision support tools incorporating magnetic resonance imaging (MRI) findings in predicting clinically significant prostate cancer (csPCa). PATIENTS AND METHODS: We retrospectively included men who underwent prostate MRI and subsequent targeted and/or systematic prostate biopsies in two large European centres. Available decision support tools were identified by a PubMed search. Performance was assessed by calibration, discrimination, decision curve analysis (DCA) and numbers of biopsies avoided vs csPCa cases missed, before and after recalibration, at risk thresholds of 5%-20%. RESULTS: A total of 940 men were included, 507 (54%) had csPCa. The median (interquartile range) age, prostate-specific antigen (PSA) level, and PSA density (PSAD) were 68 (63-72) years, 9 (7-15) ng/mL, and 0.20 (0.13-0.32) ng/mL2 , respectively. In all, 18 multivariable risk calculators (MRI-RCs) and dichotomous biopsy decision strategies based on MRI findings and PSAD thresholds were assessed. The Van Leeuwen model and the Rotterdam Prostate Cancer Risk Calculator (RPCRC) had the best discriminative ability (area under the receiver operating characteristic curve 0.86) of the MRI-RCs that could be assessed in the whole cohort. DCA showed the highest clinical utility for the Van Leeuwen model, followed by the RPCRC. At the 10% threshold the Van Leeuwen model would avoid 22% of biopsies, missing 1.8% of csPCa, whilst the RPCRC would avoid 20% of biopsies, missing 2.6% of csPCas. These multivariable models outperformed all dichotomous decision strategies based only on MRI-findings and PSAD. CONCLUSIONS: Even in this high-risk cohort, biopsy decision support tools would avoid many prostate biopsies, whilst missing very few csPCa cases. The Van Leeuwen model had the highest clinical utility, followed by the RPCRC. These multivariable MRI-RCs outperformed and should be favoured over decision strategies based only on MRI and PSAD.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Davik P, Remmers S, Elschot M, et al. Performance of magnetic resonance imaging-based prostate cancer risk calculators and decision strategies in two large European medical centres. BJU Int. 2023. PMID: 37607322. doi:10.1111/bju.16163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。